Composition and method for the diagnosis and treatment of iron-related disorders

Patent metadata

Field	Value
Publication number	US-10822403-B2
Application number	US-201816179515-A
Country	US
Kind code	B2
Filing date	Nov 2, 2018
Priority date	Dec 14, 2011
Publication date	Nov 3, 2020
Grant date	Nov 3, 2020

Abstract

Provided herein are methods of using the antibodies that bind to RGMc to treat and diagnose iron-related disorders.

First claim

We claim:

1. A humanized monoclonal anti-Repulsive Guidance Molecule c (RGMc) antibody that comprises a variable heavy chain region comprising a complementary determining region (CDR)1 with an amino acid sequence set forth in SEQ ID NO:17, a CDR2 with an amino acid sequence set forth in SEQ ID NO:18; a CDR3 with an amino acid sequence set forth in SEQ ID NO:19; and a variable light chain region comprising a CDR1 with an amino acid sequence set forth in SEQ ID NO:20, a CDR2 with an amino acid sequence set forth in SEQ ID NO:21, and a CDR3 with an amino acid sequence set forth in SEQ ID NO:22.

2. The humanized monoclonal anti-RGMc antibody of claim 1 , wherein the antibody is affinity matured.

3. The humanized monoclonal anti-RGMc antibody of claim 2 , wherein the variable light chain region has the amino acid sequence set forth in SEQ ID NO:6.

4. The humanized monoclonal anti-RGMc antibody of claim 3 , wherein the antibody comprises a heavy chain immunoglobulin constant domain, which is a human IgG1 constant domain.

5. The humanized monoclonal anti-RGMc antibody of claim 1 , wherein the variable heavy chain region has the amino acid sequence set forth in SEQ ID NO:5 with up to one amino acid difference in a framework region.

6. The humanized monoclonal anti-RGMc antibody of claim 3 , wherein the variable heavy chain region has the amino acid sequence set forth in SEQ ID NO:5 with up to one amino acid difference in a framework region.

7. The humanized monoclonal anti-RGMc antibody of claim 5 , wherein the antibody comprises a heavy chain immunoglobulin constant domain, which is a human IgG1 constant domain.

8. The humanized monoclonal anti-RGMc antibody of claim 6 , wherein the antibody comprises a heavy chain immunoglobulin constant domain, which is a human IgG1 constant domain.

9. A pharmaceutical composition comprising the humanized monoclonal antibody of claim 1 and a pharmaceutically acceptable carrier.

10. A pharmaceutical composition comprising the humanized monoclonal antibody of claim 8 and a pharmaceutically acceptable carrier.

11. The pharmaceutical composition of claim 9 , wherein the humanized monoclonal antibody and pharmaceutically acceptable carrier are in a lyophilized form.

12. The pharmaceutical composition of claim 10 , wherein the humanized monoclonal antibody and pharmaceutically acceptable carrier are in a lyophilized form.

13. The pharmaceutical composition of claim 9 , wherein the humanized monoclonal antibody and pharmaceutically acceptable carrier are in a solution form.

14. The pharmaceutical composition of claim 10 , wherein the humanized monoclonal antibody and pharmaceutically acceptable carrier are in a solution form.

Assignees

• Abbvie Deutschland
• Abbvie Inc

Inventors

• Mueller Bernhard
• Popp Andreas
• Perez Jennifer M

Classifications

• C07K16/28 Primary

  against receptors, cell surface antigens or cell surface determinants · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• A61P7/06

  Antianaemics · CPC title